U.S. FDA Warning Letter To Sichuan Pharma Only Tip Of The Iceberg For China State-Owned Company
This article was originally published in PharmAsia News
WASHINGTON and SHANGHAI - U.S. FDA issued Sichuan Pharmaceutical Co., Ltd. a warning letter Sept. 9 for significant deviations from current good manufacturing practices in the manufacture of active pharmaceutical ingredients. The warning letter adds more woes to the troubled China state-owned enterprise, and the Chengdu government is looking for a basement price to unload the company
You may also be interested in...
U.S. FDA issues five warning letters to foreign drug makers for failing to register their products as agency beefs up efforts to ensure international compliance.
U.S. FDA Issues Warning Letters To Chinese Firms As Agency Tightens Foreign Field Inspections Program
The agency requests 16 more inspectors in China in an effort to boost enforcement and training.
The broad outlines of the timing and scope of a U.S. legislative response to the global pharmaceutical supply chain crisis are taking shape